Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Grigoryan, Anna ^a   Hall, H Irene ^a   Durant, Tonji ^a   Wei, Xiangming ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b McKing Consulting Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DELAYED DIAGNOSIS; DISEASE COURSE; ETHNICITY; FEMALE; HETEROSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MORTALITY; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; SEXUAL BEHAVIOR; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES;

EID: 84887212498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004445     Document Type: Article

References (29)

1. Lee LM, Karon JM, Selik R, Neal JJ, Fleming P (2001) Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 285: 1308-1315.
2. Murphy EL, Collier AC, Kalish LA (2001) Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135: 17-26.
3. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, et al. (2007) Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21(6): 685-692.
4. + cell strata. Ann Intern Med 138: 620-626.
5. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, et al. (2001) Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 15: 1707-1715.
6. Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, et al. (2005) Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 38: 96-103.
7. Van Asten LC, Boufassa F, Schiffer V, Brettle RP, Robertson JR, et al. (2003) Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level. Eur J Public Health 13: 347-349.
8. Des Jarlais DC, Perlis T, Arasteh K, Hagan H, Milliken J, et al. (2004) "Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001. J Acquir Immune Defic Syndr 35(2): 158-166.
9. Weinhardt LS, Carey MP, Johnson BT, Bickham NL (1999) Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997. Am J Public Health 89: 1397-1405.
10. Hall IH, McDavid K, Ling Q, Sloggett A (2006) Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann Epidemiol 16: 824-833.
11. Centers for Disease Control and Prevention (2007) HIV/AIDS surveillance report, 2005, Vol. 17. Rev. ed. AtlantaGA: US Department of Health and Human Services, CDC, Available: http://www.cdc.gov/hiv/topics/ surveillance/resources/reports/2005report/default.htm. Accessed 2008 Mar 31.
12. Amato D (1988) A generalized Kaplan-Meier estimator for heterogeneous populations. Commun Stat Theory Methods 17: 143-154.
13. Egger M, May M, Cheêne G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 360: 119-129.
14. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, et al. (2003) Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 169(7): 656-661.
15. Andersen R, Bozzette S, Shapiro M, St Clair P, Morton S, et al. (2000) Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. Health Serv Res 35(2): 389-416.
16. Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, et al. (1999) A comparison of exposure groups in the EuroSIDA Study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 22(4): 369-378.
17. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, et al. (2003) Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362(9392): 1267-1274.
18. Muga R, Egea JM, Sanvisens A, Arnal J, Tural C, et al. (2004) Impact of injecting drug use on the interruption of antiretroviral therapies. J Epidemiol Commun Health 58: 286-287.
19. Kleeberger CA, Buechner J, Palella F, Detels R, Riddler S, et al. (2004) Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS 18: 683-688.
20. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, et al. (1998) Barriers to use of free antiretroviral therapy in injection drug users. JAMA 280(6): 547-549.
21. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T (2002) Directly observed therapy for the treatment of people with human immunodeficiency virus infection: A work in progress. Clin Infect Dis 34(7): 984-990.
22. Kohli R, Lo Y, Howard AA, Buono D, Floris-Moore M, et al. (2005) Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 41: 864-872.
23. Kellerman SE, Lehman JS, Lansky A, Stevens MR, Hecht FM, et al. (2002) HIV testing within at-risk populations in the United States and the reasons for seeking or avoiding HIV testing. J Acquir Immune Defic Syndr 31: 202-210.
24. Centers for Disease Control and Prevention (2006) Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 55(RR-14): 1-17.
25. Couturier E, Schwoebel V, Michon C, Hubert JB, Delmas MC, et al. (1998) Determinants of delayed diagnosis of HIV infection in France, 1993-1995. AIDS 12: 795-800.
26. Poundstone K, Chaisson R, Moore R (2001) Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 15: 1115-1123.
27. Manfredi R (2002) HIV disease and advanced age: An increasing therapeutic challenge. Drugs Aging 19: 647-669.
28. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, et al. (2001) Rates of disease progression by baseline of CD4 cell count and viral load after initiating triple-drug therapy. JAMA 286: 2568-2577.
29. U.S. Department of Health and Human Services (2008 Jan 29) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available: http://aidsinfo.nih.gov. Accessed 2008 Sept 30.